

- **Letter to Editor**

Importance of Bioactive Peptides Derived from Cyanobacteria

Bahareh Alizadeh, Maryam Tabarzad

Trends in Peptide and Protein Sciences, Vol. 9 No. 1 (2024), Page 1-5 (e1)

<https://doi.org/10.22037/tpps.v9i1.44444>

- **Original Articles**

In Silico Evaluation of Antimicrobial Potential of Amaranth, Chia and Quinoa Peptides Released During the Simulated Gastric Digestion and Their Effects on *Helicobacter pylori*

Esra Menfaatli, Murat Kavruk, Ersin Gundeger

Trends in Peptide and Protein Sciences, Vol. 9 No. 1 (2024), Page 1-8 (e2)

<https://doi.org/10.22037/tpps.v9i1.45658>

- **Mini-Review Article**

Cyanophycin as a Cyanobacterial Granule Polypeptide: Potential Sources and Applications

Maryam Tabarzad, Mohammad Vahid Tabarzad, Tahereh Hosseinabadi

Trends in Peptide and Protein Sciences, Vol. 9 No. 1 (2024), Page 1-9 (e3)

<https://doi.org/10.22037/tpps.v9i1.46884>

Application of Phage Display in Medicine and Pharmaceuticals

Mojgan Bandehpour, Bahram Kazemi

Trends in Peptide and Protein Sciences, Vol. 9 No. 1 (2024), Page 1-8 (e4)

<https://doi.org/10.22037/tpps.v9i1.46894>

Iron Regulatory Proteins and Pharmacological Iron Modulators: Therapeutic Implications

Fatemeh Pirivand, Keyvan Ramezani

Trends in Peptide and Protein Sciences, Vol. 9 No. 1 (2024), Page 1-10 (e5)

<https://doi.org/10.22037/tpps.v9i1.46862>

About the Journal

The Trends in Peptide and Protein Sciences is a peer-reviewed, online-only (previously print-online), scientific journal owned by Protein Technology Research Center, Shahid Beheshti University of Medical Sciences and documents in all important aspects of the research in peptides and proteins focusing on analytics and

impurities, bioinformatics, biopharmaceuticals and vaccines, biotechnology, chemical synthesis, conformational analysis, design and development of protein therapeutics, determination of structure, enzymology, folding and sequencing, formulation and stability, function, genetics, immunology, kinetics, modeling, molecular biology, pharmacokinetics and pharmacodynamics of therapeutic proteins

and antibodies, pharmacology, protein engineering and development, protein-protein interaction, proteomics, purification/production, simulation, thermodynamics and hydrodynamics and protein biomarkers. The aim of this Journal is to publish high quality original research articles, reviews, short communications and letters and to provide a medium for scientists and researchers to share their findings from the area of peptides and proteins. The Trends in Peptide and Protein Sciences is published in collaboration with Iranian Association of Pharmaceutical Scientists.

From volume 3 (2018) of TPPS, articles are continuously published online only, as soon as the review process is completed.

The Trends in Peptide and Protein Sciences has been granted the Scientific-Research Rank by the Commission of Medical Sciences Journals of Ministry of Health, Treatment and Medical Education of I.R. Iran.

The Journal of "Trends in Peptide & Protein Sciences" is indexed in:

- ✓ International Institute of Organized Research (I2OR)
- ✓ Open-J-Gate
- ✓ Science Library Index
- ✓ Chemical Abstract Service
- ✓ DOAJ
- ✓ IndexCopernicus
- ✓ Citefactor
- ✓ Asian Science Citation Index (ASCI)
- ✓ Index Medicus for the Eastern Mediterranean Region (IMEMR)
- ✓ Embase

The Journal of "Trends in Peptide & Protein Sciences" is available in:

[Google Scholar](#)

The Journal of "Trends in Peptide & Protein Sciences" is a member of:

[Directory of Open Access scholarly Resources \(ROAD\)](#)

[ORCID](#)

Editorial Board

Chairperson

Reza Aboofazeli;

Professor of Pharmaceutics, Department of Pharmaceutics and Pharmaceutical Nanotechnology, School of Pharmacy & Protein Technology Research Center, Shahid Beheshti University of Medical Sciences, Tehran, I.R. of Iran.

Email: rafoofazeli@sbmu.ac.ir

Editor-in-Chief

Bahram Kazemi;

Professor of Biotechnology, Department of Biotechnology, School of Medicine & Cellular and Molecular Biology Research Center, Shahid Beheshti University of Medical Sciences, Tehran, I.R. of Iran.

Email: kazemi@sbmu.ac.ir

Managing Editor

Maryam Tabarzad;

Assistant Professor of Pharmaceutical Biotechnology, Protein Technology Research Center, Shahid Beheshti University of Medical Sciences, Tehran, I.R. of Iran.

mail: m_tabarzad@sbmu.ac.ir

Editorial Team

Mojgan Bandehpour;

Associate Professor of Biotechnology, Cellular and Molecular Biology Research Center and School of Advanced Technologies in Medicine, Shahid Beheshti University of Medical Sciences, Tehran, I.R. of Iran.

Email: m.bandehpour@sbmu.ac.ir

Dave Barlow;

Reader in Computational & Molecular Biophysics, Institute of Pharmaceutical Sciences, Franklin-Wilkins Building, King's College London, London, UK.

Email: dave.barlow@kcl.ac.uk

Adil Denizli;

Professor of Chemistry, Biochemistry Division, Department of Chemistry, Hacettepe University, Ankara, Turkey.

Email: denizli@hacettepe.edu.tr

Mehrdad Faizi;

Professor of Toxicology and Pharmacology, Department of Toxicology and Pharmacology, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, I.R. of Iran.

Email: m.faizi@sbmu.ac.ir

Mohammad Ali Faramarzi;

Professor of Pharmaceutical Biotechnology, Department of Pharmaceutical Biotechnology, Faculty of Pharmacy & Biotechnology Research Center, Tehran University of Medical Sciences, Tehran, I.R. of Iran.

Email: faramarz@tums.ac.ir

Seyed Mohsen Foroutan;

Professor of Pharmaceutics, Department of Pharmaceutics and Pharmaceutical Nanotechnology, School of Pharmacy & Protein Technology Research Center, Shahid Beheshti University of Medical Sciences, Tehran, I.R. of Iran.

Email: mforoutan@sbmu.ac.ir

Mohammad Hossein Ghahremani;

Professor of Toxicology and Pharmacology, Department of Toxicology and Pharmacology, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, I.R. of Iran.

Email: mhghahremani@tums.ac.ir

Younes Ghasemi;

Professor of Pharmaceutical Biotechnology, Department of Pharmaceutical Biotechnology, School of Pharmacy, Shiraz University of Medical Sciences, Shiraz, I. R. of Iran.

Email: ghasemiy@sums.ac.ir

Mohammad Hassan Houshdar Tehrani;

Professor of Pharmaceutical Chemistry, Department of Pharmaceutical Chemistry, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, I.R. of Iran.

Email: m_houshdar@sbmu.ac.ir

Hamed Jafar-Nejad;

Professor of Molecular & Human Genetics, Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, Texas, United States.

Email: hamedj@bcm.edu

Jayne Lawrence;

Professor of Biophysical Pharmaceutics, Division of Pharmacy & Optometry, School of Health Sciences, University of Manchester, United Kingdom.

Email: jayne.lawrence@manchester.ac.uk

Mohammad Hossein Morowvat;

Associate Professor of Pharmaceutical Biotechnology, Department of Pharmaceutical Biotechnology, Pharmaceutical Sciences Research Center, Shiraz University of Medical Sciences, Shiraz, I.R. of Iran.

Email: mhmorowvat@sums.ac.ir

Seyed Nasser Ostad;

Professor of Toxicology and Pharmacology,
Department of Toxicology and Pharmacology,
Faculty of Pharmacy, Tehran University of
Medical Sciences, Tehran, I.R. of Iran.

Email: ostadnas@tums.ac.ir

Mohammad Ramezani;

Professor of Pharmaceutical Biotechnology,
Department of Biotechnology, Pharmaceutical
Research Center, School of Pharmacy,
Mashhad University of Medical Sciences,
Mashhad, I.R. of Iran.

Email: ramezanim@mums.ac.ir

Bijan Ranjbar;

Professor of Biophysics, Department of
Biophysics, Faculty of Biological Sciences,
Tarbiat Modares University, Tehran, I.R. of
Iran.

Email: ranjbarb@modares.ac.ir

Soraya Shahhosseini;

Professor of Pharmaceutical Chemistry,
Department of Pharmaceutical Chemistry,
School of Pharmacy, Shahid Beheshti
University of Medical Sciences, Tehran, I.R. of
Iran.

Email: s_shahoseini@sbmu.ac.ir

Emad Tajkhorshid;

Professor of Biochemistry, Department of
Biochemistry; Center for Biophysics and
Quantitative Biology; Beckman Institute for
Advanced Science and Technology, University
of Illinois at Urbana-Champaign, United States.

Email: emad@life.illinois.edu

Alireza Vatanara;

Professor of Pharmaceutics, Department of
Pharmaceutics, Faculty of Pharmacy, Tehran
University of Medical Sciences, Tehran, I.R. of Iran.

Email: vatanara@tums.ac.ir

English Editor**Elahe Ahmadian;**

Shahid Beheshti University of Medical
Sciences, Tehran, I.R. of Iran.

Email: elaheahmadian@ymail.com.

Layout Editor**Nooshin Meraji;**

Shahid Beheshti University of Medical
Sciences, Tehran, I.R. of Iran.

Email: tipps@sbmu.ac.ir

Electronic Submission of Manuscript

Manuscripts must be submitted online by the
Corresponding Author to the *Trends in Peptide
and Protein Sciences* at:

<http://journals.sbm`u.ac.ir/protein/about/submissions#onlineSubmissions>.

First-time users are required to register at
<http://journals.sbm.ac.ir/protein/user/register>
before submitting a manuscript. Straightforward
login and registration procedures can be found on
the website.

Note: you should mark "Author" as your role on
"My Profile".

By submission, the author(s) confirm that the
manuscript (or any parts of it) has not been
published previously or is not under
consideration for publication in another journal.
Previous presentation in any congresses should
be mentioned as a footnote in Title page and
also stated in the Covering Letter. Furthermore,
any illustrations, structures or tables that have
been published elsewhere must be reported, and
copyright permission for reproduction must be
obtained.

Categories of Articles

The *Trends in Peptide and Protein Sciences* publishes the articles in the following categories:

- **Original Research Articles** should be divided into the following sequence of sections: Title page, Abstract, Keywords, Introduction, Materials and Methods, Results and Discussion, Conclusion, Acknowledgements, Competing Interests and References.
- **Review Articles** inform readers of the state-of-the-art of a particular area, provide a critical view, or a historical perspective. They should be comprehensive, critical, and balanced. These are contributed by scientists who are leading specialists in their field of expertise, normally at the invitation of the Editors. Authors wishing to contribute a review paper are advised first to contact one of the members of Editorial Board.
- **Mini-reviews** with the range of 7000-10000 words, which include at least 75 references (excluding figures, structures, photographs, schemes, tables etc.), will be published.
- **Systematic Reviews**, as the highest quality evidence on a research topic, are prepared with the purpose of delivering a summary of all the already available published research in response to a research question. Systematic reviews should be prepared with minimum 100 references (excluding figures, structures, photographs, schemes, tables etc.) according to PRISMA guidelines (www.prisma-statement.org).
- **Book Reviews** on both recently print and electronic relevant books will be published by the journal. For arrangement, book review proposals (including the title of the

book, publisher, year of publication and book summary) should be sent initially to the Editor-in-Chief of the journal. Suggestions are welcome.

- **Short Communications** are reserved for short reports of highly important and noteworthy findings in protein and peptide sciences, useful computer softwares, along with a description of relevant applications and the announcement of novel protocols. Short Communications should not exceed 2500 words in length, including references, tables and figures. These manuscripts are followed the peer-review process and will be considered for fast publication, if accepted.
- **Letter to the Editors** are intended to stimulate discussion in areas of general concern and controversy in protein and peptide sciences. They should be written in a continuous style and should normally not exceed 1500 words in length and contain no more than one figure or table.

Covering Letter

All manuscripts must be accompanied by a signed cover letter in the “Comments for the Editor” and submitted by the Corresponding Author during online submission. Other than any comments, you would like to write to the editor, the following items must be addressed in this letter; importance of the work and its relevance to the journal’s scope, the name, address, telephone number, fax number, and e-mail address of the Corresponding Author. The author has to confirm in written that the manuscript (or any parts of it) has not been published previously or is not under consideration for publication in another journal. Previous presentation in any congresses should

be stated in the covering letter. You are also required to mention the names of two potential preferred referees that could be considered for reviewing your manuscript.

Highlights

Highlights are required for this journal. They consist of a short collection of bullet points that convey the core findings of the manuscript, including 3 to 5 bullet points (maximum 85 characters, including spaces, per bullet point), and should be submitted in a separate page following the Title page.

Graphical Abstract

A colored graphic could be included with each manuscript. This must be presented in a separate page following the Abstract (preferred file types are TIFF, PNG, JPEG and Power Point, minimum 300 dpi). A graphical abstract, not exceeding 30 words along with the illustration, helps to summarize the contents of the manuscript in a concise pictorial form.

Preparation of Manuscripts

General Instructions

Manuscripts should be prepared according to the following mentioned stylistic. The Editors have the right to make editorial corrections and additional changes with the knowledge and approval of the Corresponding Author. The word processing format for the manuscript file must be Microsoft Word. The main manuscript should contain:

- Title Page

The title page should include:

- A concise and informative title:
- The name(s) of the author(s)

- The affiliation(s) of the author(s)
- The e-mail address of the authors
- The ORCID ID of the authors or at least the first and corresponding authors
- The e-mail address, ORCID ID, telephone and fax numbers of the Corresponding Author
- Running title (short comprehensive title contains maximum 85 characters)

The title of the article should be precise and brief. Authors should avoid the use of non-standard abbreviations. Use initial capital letter for each title word. The authors will be required to provide their full names and the institutional affiliations by numbers in superscripts. The Corresponding Author should be remarked with a superscripted asterisk. Authors are expected to consider carefully the list and order of authors before submitting their manuscript.

- Abstract

The abstract of an article should be a clear, concise and accurate summary of the work, having no more than 300 words. Use of abbreviations should be avoided and the references should not be cited in the abstract.

- Keywords

Author(s) should provide 4 to 6 keywords, which can be used for indexing purposes. They should be in alphabetic order and first capital letter, separated with semicolons.

- Abbreviations (if required)

The full term of each abbreviation should be written in the text before its first use. Standard and well-known abbreviations do not need explanation. All nomenclature, including gene names and symbols, should be used in a scientifically accurate manner following the nomenclature conventions adopted by the scientific community.

- Main text

When submitting a manuscript, ensure that the following sections are included separately; Introduction, Materials and Methods, Results and Discussion, Conclusion, Acknowledgements, Competing Interests and References. Introduction should be concise, without subheadings and indicates the purpose and rational of the study. Materials and Methods provide sufficient detail to allow the work to be reproduced, with details of supplier and catalogue number when appropriate. Methods already published should be indicated by a reference, only relevant modifications should be described. Discussion should explore the significance of the results of the work, not repeat them. It may contain subheadings in some sections. The detailed data should not be repeated again in Conclusion. In the case of Short Communications, Result and Discussion and Conclusion could be merged.

- Acknowledgements

All contributors who do not meet the criteria for authorship should be covered in this section. Financial and material supports should also be acknowledged.

- Competing Interests

Author(s) warrant that any financial interests, direct or indirect, that exist or may be perceived to exist for individual contributors in connection with this manuscript have been disclosed in the Covering Letter and Manuscript.

- Ethical consideration

Author(s) herein confirm that all human and/or animal studies undertaken, are in compliance with the regulations of their institution(s) and generally accepted guidelines governing such work. In any studies that involve experiments on human subjects, work must be conducted in accordance with the [Declaration of Helsinki](#).

For the experiments on animal subjects, the compliance with [National Institutes of Health guidelines for the human use of laboratory animals](#), should be declared in text.

Author(s) warrant that this manuscript contains no violation of any existing copyright or other third party right or any materials of an obscene, indecent, libelous, or otherwise unlawful nature and that to the best of their knowledge the manuscript does not infringe the rights of others.

- Author contribution

All persons who listed as authors, must certify that participated sufficiently in the work and take public responsibility for the content of appropriate portions.

Example of author contribution statement:

A.B. and B.C. conceived of the presented idea. A.B. developed the theory and performed the computations. C.D. and D.E. verified the analytical methods. B.C. encouraged A.B. to investigate [a specific aspect] and supervised the findings of this work. All authors discussed the results and contributed to the final manuscript.

- Funding Support

Financial and material support should be acknowledged, here.

- References

All references should be listed accordance to the Harvard style. Harvard is an 'author/date' system, so your in-text citation consists of author(s) and year of publication. At the end, the authors should be listed in alphabetical order. For more guides, use the online information at <http://guides.is.uwa.edu.au/harvard>.

If using *EndNote*, cite according to Author-Date style

• In-text Citation

For Harvard in-text citation, the last name of the author(s) and the year of publication are

appeared in parenthesis beside any quotation or paraphrase of a source.

•• Single citation

Number of authors	In-text citation example
1 author	(Davis, 2019)
2 authors	(Davis and Barrett, 2019)
+3 authors	(Davis et al., 2019)

•• Multiple citations at the same point

When you need multiple citations to appear at the same point in your text – for example, when you refer to several sources with one phrase – you can present them in the same set of parenthesis, separated by semicolons. List them in order of publication date.

Example

L-captopril, L-penicillamine and 2-thiopheneboronic acid inhibits...(Gillner, et al., 2009; Uda and Creus, 2011; Greenfield and Harlow, 2014; Starus, et al., 2015).

•• Multiple sources with the same author and date

If you cite multiple sources by the same author which were published in the same year, it is important to distinguish between them in your citations. To do this, insert an 'a' after the year in the first one you reference, a 'b' in the second, and so on.

Example

The results of the first study (Woodhouse, 2018a) were inconclusive, but a follow up study (Woodhouse, 2018b) achieved a clearer outcome.

•• No publication date

When a source does not have a clear publication date – for example, a constantly updated

reference source like Wikipedia or an obscure historical document which cannot be accurately dated – you can replace it with the words 'no date'. For example (Scribbr, no date).

Note that when you do this with an online source, you should still include an access date in References, as in the example; Scribbr (no date) *How to structure a dissertation*. Available at: <https://www.scribbr.co.uk/category/thesis-dissertation/> (Accessed: 14 February 2020).

•• No author (standards, online reports, governmental publication and pharmacopeial catalogues)

When a source lacks a clearly identified author, there is often an appropriate corporate source – the organization responsible for the source – whom you can credit as author instead, as in the Google and Wikipedia examples above.

Example

(Collins English dictionary, 2012) or (WHO, 2020), (BP, 2018).

•• Conference Papers/ Poster /Proceeding

Galar et al. (2014) identified that the risks of...SMART risk assessments...(Galar et al. 2014).

•• Dissertation (Undergraduate or Masters)

Vickers (2008) noted that the impact of technology has changed the way spaces within a library building are provided... Learning spaces and services provided are changing due to technological advances (Vickers 2008)...

•• Patent

Timothy James Hollis and Fengshun Tan (2017) patented the...The helical gradient coil demonstrates...(Hollis and Tan, 2017).

Tips for citing

- If the author(s) name appears in the text as part of the body of the assignment, then the year will follow in round brackets, e.g. According to Smith (2017).

- The abbreviations *ibid* and *idem* should not be used within the Harvard referencing system.
- Some authors have the same surname and works published in the same year, if this is the case use their initial to distinguish between them, e.g. When looking at the average income it was found that...(Williams, A. 2009). However, it was also discovered that...(Williams, J. 2009).
- For items where the author is a corporation, cite the name of the corporation in full e.g. Birdwatching in the woods...(Woodland Trust 2016), unless their abbreviation is well-known e.g. The governance of the network...(BBC 2017).
- If a work is designated as Anonymous, use Anon instead of the creator's name, e.g. The literature suggests that...(Anon 1816).
- If the year of publication is not given, but can be established, it should be supplied.
- **Citation in Reference/ Bibliography**
 - **Journal articles**

Bernocchi, B., Carpentier, R., Lantier, I., Ducournau, C., Dimier-Poisson, I. and D. Betbeder, (2016). "Mechanisms allowing protein delivery in nasal mucosa using NPL nanoparticles." *Journal of Controlled Release*, **232**: 42–50.

Bates, R. C., Stith, B. J. and K. E. Stevens, (2015). "Increasing pro-survival factors within whole brain tissue of Sprague Dawley rats via intracerebral administration of modified valproic acid." *Journal of Pharmacological Sciences*, **128**(4): 193-201.
 - **Book**

Montgomery, D. C. (2005). *"Design and Analysis of Experiments,"* 6th ed., John Wiley & Sons, Inc. New Jersey, pp. 119-159.

Silbey, R. J., Alberty, R. A. and M. G. Bawendi, (2005). *"Physical Chemistry,"* 4th ed., John Wiley & Sons, Inc., New Jersey, pp. 74-101.
 - **Book chapter**
 - **One author**

Chien, Y. W. (1991). "Transdermal Route of Peptide and Protein Drug Delivery." In: V. H. L. Lee (Ed.), *Peptide and Protein Drug Delivery*, Marcel Dekker, Inc., New York, pp. 667-689.
 - **Two authors**

Pearlman, R. and T. H. Nguyen, (1991). "Analysis of Protein Drugs." In: V. H. L. Lee (Ed.), *Peptide and Protein Drug Delivery*, Marcel Dekker, Inc., New York, pp. 247-301.
 - **Three and more author**

Banerjee, P. S., Hosny, E. A. and J. R. Robinson, (1991). "Parenteral Delivery of Peptide and Protein Drugs." In: V. H. L. Lee (Ed.), *Peptide and Protein Drug Delivery*, Marcel Dekker, Inc., New York, pp. 487-543.
 - **Conference Paper/ Poster/Proceeding**
 - **Paper**

Galar, D., Sandborn, P., Kumar, U. and C-A. Johansson, (2014). "SMART: integrating human safety risk assessment with Asset Integrity." In: G. Dalpiaz, R. Rubini, G. D'elia, M. Cocconcelli, F. Chaari, R. Zimroz, W. Bartelmus and M. Haddar, eds. *Advances in condition monitoring of machinery in non-stationary operations, proceedings of the third international conference on condition monitoring of machinery in non-stationary operations*, CMMNO, 2013, Ferrara, Italy. Berlin: Springer, pp. 37–59.

Redknap, M., (2004). "Viking-age settlements in Wales and the evidence from Llanbedrgoch." In: J. Hines, A. Lane and M. Redknap, eds. *Land, sea and home, proceedings of a conference on Viking-period settlement*, July

2001, Cardiff. Leeds: Manay Publishing, pp. 139–175.

For Online/Electronic versions add [Available from: URL or doi:]

Fujikami, S., Sumi, T., Yagiu, R. and Nagai, Y., (2015). "Fast device discovery for vehicle-to-pedestrian communication using wireless LAN." In: Institute of Electrical Engineers (IEEE). *12th Annual IEEE Consumer Communications and Networking Conference (CCNC 2015)*, 9–12 January 2015, Las Vegas, Nevada, USA [online]. New York: Institute of Electrical and Electronics Engineers. pp. 35–40. [Viewed 10 December 2015]. Available from: doi: 10.1109/CCNC.2015.7157943

– *Poster*

Bazela, C., Grant, V. and A. Tucker, (2014). "History of medicine 2.0: using creative media to enhance information literacy teaching for 1st year medical students [poster]." In: *LILAC*, 23–25 April 2014, Sheffield, United Kingdom.

For Online/Electronic versions add [Available from: URL or doi:]

Kleinschmidt, T., Fuhr, O. and Wietfeld, C., (2016). "Synchronised charging of electric vehicles with distant renewable energy resources [Poster]." In: O. Altinas, E. Ekici, M. Tsai, M. Speulcre, B. Bloessi, and Y-L. Wei. eds. *2016 IEEE Vehicular Networking Conference (VNC)*, 8–10 December 2016, Columbus, OH, USA [online]. New York: Institute of Electrical and Electronics Engineers. Available from: doi: 10.1109/VNC.2016.7835983

– *Proceeding*

Dalpiaz, G., Rubini, R., D'elia, G., Cocconcelli, M., Chaari, F., Zimroz, R., Bartelmus, W. and

M. Haddar, eds., (2014). "*Advances in condition monitoring of machinery in non-stationary operations, proceedings of the third international conference on condition monitoring of machinery in non-stationary operations*," CMMNO, 2013, Ferrara, Italy. Berlin: Springer.

Orman, W. and M.J. Valteau, eds., (2014). "*Proceedings of the 38th annual Boston University Conference on language development*," 2013, Boston, Massachusetts. Somerville, MA; Cascadilla Press. Volume 2.

For Online/Electronic versions add [Available from: URL or doi:]

Institute of Electrical and Electronics Engineers (IEEE)., (2015). *12th Annual IEEE Consumer Communications and Networking Conference (CCNC 2015)*, 9–12 January 2015, Las Vegas, Nevada, USA [Online]. New York: Institute of Electrical and Electronics Engineers. [Viewed 10 December 2015]. Available from: http://ieeexplore.ieee.org/xpl/tocresult.jsp?asf_pun=7151874

Note that the name of the conference should be used as the author if an individual author, or corporate author cannot be identified

•• *Dissertation*

Liu, Z. (2012). "*Metabolic Engineering of Recombinant Protein Production by Saccharomyces cerevisiae*." Göteborg: Chalmers University of Technology, Sweden.

•• *Web page*

Cohen, N. (2009). *DNA, RNA and protein formation: Track 1*. Available at: <http://www.open.edu/openlearn/science-maths-technology/science/biology/dna-rna-and-protein-formation> (accessed 2016-09-12).

•• Patent

Name of inventor (if applicable) (Year patent granted). *"Title of patent." Applicant of patent.* Date patent granted (if applicable). Date of application. Official patent series Patent Serial Number.

Example

Hollis T. J. and F. Tan, (2017). "Helical gradient coil for magnetic resonance imaging apparatus." *GE Medical Systems Global Technology Company LLC*. 10 January. Appl: 20 August 2012. GB Patent GB2494259.

•• Online reports

Use "World Health Organization" as the author. Place the year next. Add the title of the report next. Place the website at the end.

Example

World Health Organization. (2020, September 22). "Tobacco responsible for 20% of deaths from coronary heart disease." Retrieved from <https://www.who.int/news-room/detail/22-09-2020-tobacco-responsible-for-20-of-deaths-from-coronary-heart-disease>

•• Government publications

Government Agency OR Last name, First Initial., (Year published). *Title of document or article.* City published: Publisher, Page(s).

Example

Pennsylvania Department of Transportation, (2012). *BicyclePA Routes*. Harrisburg: PENNDOT, p.1.

•• Standards

Organisation Responsible for the Standard. Standard number - Name of standard [Internet]. Year [revision DD Mon YYYY; cited YYYY Mon DD]. Available from: URL

Example

Australia New Zealand Food Standards Code. Standard 1.2.5 - Date marking of packaged food

[Internet]. 2012 [revised 11 Oct 2012; cited 2019 May 20]. Available from: <http://www.comlaw.gov.au>
Standards Australia. AS ISO 15189-2013 - Medical laboratories: requirements for quality and competence [Internet]. 2013 [cited 2019 Jan 15]. Available from: <https://www.saiglobal.com>

•• Pharmacopoeia (print)

Title of work. Edition. Vol. #, volume name. Place of publication: Publisher; Year of publication. Entry title; Page/s of entry.

Example

British Pharmacopoeia. Vol. 1. London: Medicines and Healthcare Products Regulatory Agency; 2018. Disodium hydrogen phosphate; p. 833-4.

The United States Pharmacopeia. National formulary. Vol. 1. Rockville (MD): United States Pharmacopoeial Convention; 2017. Collodion; p. 1076

- **Tables and Figures** should be embedded at the end of the manuscript file. They must be cited in the text consecutively with Arabic numerals (Figure 1 or Table 1) and presented in separate pages. Accepted File formats for figures are TIFF, PNG and JPEG at 600 dpi or higher. Graphs and charts are considered equally to figures and accepted in the formats of TIFF, PNG and JPEG. Tables should be in Word Table format, not inserted as graphics. They should be self-explanatory, cited in the main text. Tables with their captions should be presented following the References on a separate page. A table caption should be a brief descriptive title and all other important information must be presented in the footnotes. Add Figures and Figures' captions separately following the Tables. Equations must be presented by the equation tab of the Word.

Chemical structures and reactions are presented by schemes. Equations and Schemes are also cited sequentially with Arabic numerals (Equation 1 or Scheme 1).

Publication Ethics

TPPS follows the international regulations against scientific misconduct including fabrication, falsification, [plagiarism](#), and etc. Any cases of suspected misconduct will be assessed during the peer-review and publication process based on [COPE guidelines](#).

Page Charges

There are no charges for publication in this Journal.

Authors' Agreement Form

It is mandatory that a signed [Authors' Agreement Form](#) to be sent along with the proofreading by the Corresponding Author. The Author(s) acknowledge that the publisher has the legal right to take appropriate action against the Author(s) for any violation of the terms and conditions as laid down in the Authors' Agreement Form.

Ethical considerations of animals and human studies

Authors herein confirm that all human and/or animal studies undertaken are in compliance with the regulations of their institution(s) and generally accepted guidelines governing such work. In any studies that involve experiments on human subjects, work must be conducted in accordance with the [Declaration of Helsinki](#). For the experiments on animal subjects, the compliance with [National Institutes of Health Guidelines for the Human Use of Laboratory Animals](#) should be declared in the text.

Peer-review policy (ethics and competing interest)

Invited reviewers are expected to consider the competing interests to accept the reviewing process of the manuscript. Reviewers should have no financial conflicts of interest which means that they may profit or be negatively impacted financially by the submitted research. They also should have no personal relationship or competition with the authors, also, they have not recently worked at the same institution or organization as the authors and have no current collaboration with the authors. They have not published or held grants with the authors during the last 5 years.

Post-publication discussion and correction

If authors or audiences find errors in their published article, especially errors that could affect the interpretation of data or reliability of information presented, they should notify the Editorial office by email at tipps@sbmu.ac.ir.

If, after reading the guidance, authors/audiences believe a correction or retraction is necessary for their article, they should contact the journal by email at tipps@sbmu.ac.ir.

All major errors are accompanied by a separate Erratum that provides clear details of the error and the changes that have been made to the article. This Erratum is electronically linked back to the original version. Also, a footnote on the original article displays the electronic link to the Erratum. This correction will be notified in the online issue of the journal.

Minor errors will not be accompanied by a separate Erratum. The corrected file will be replaced instead of the original version and a footnote will be added to the article detailing to the audience that the article has been corrected. Minor errors do not impact the reliability of, or the reader's understanding of, the scientific content.

Retraction will be considered if there is clear evidence that the findings are unreliable, either as a result of misconduct (e.g. data fabrication or image manipulation) or honest error (e.g. miscalculation or experimental error), or if the findings have previously been published elsewhere (redundant publication or duplicate publication). If any violation of Ethical consideration becomes evident by the Editorial office, the article will be retracted. In these situations, the “Retracted” watermark to the published version of the article will be added.

Allegation of misconduct

If the journal receives a letter raising concerns about any scientific misconduct, such as plagiarism, fabrication, falsification, copyright or intellectual property violation, break of research ethics, authorship disagreements, conflicts of interest, or any other problematic conduct that happens either pre- or post-publication, it will be discussed in the Editorial Board forum. If this misconduct is confirmed, the editor will communicate in writing with the authors stating the details of misconduct that have been claimed against the paper. The authors are given a specified period of time to respond in writing to the allegation.

If the corresponding author does not respond and/or provide sufficient rationale for the raised concern, or if established evidence is provided to the Editor that proves an ethical or scientific violation, regardless of its severity, several corrective actions according to the Editorial Board decision will make, such as publishing an erratum, expression of concern, or retraction of the article.

The authors will be notified of the Editorial Board’s decision and they may appeal the decision by sending an appeal letter to the Editorial office through tipps@sbmu.ac.ir.

Complaints and appeals

Authors or audiences can submit their complaints about the policies, procedures, or actions of the journal staff by sending an e-mail to tipps@sbmu.ac.ir.

All received complaints and appeals will be handled by the Editorial office, and the Editor-in-Chief will finalize whether any appropriate response or decision change should be made. Re-review of the manuscript may be done. The new decision made after the final considerations of the appeal will be informed to the respected individuals, applied, and announced in the online version of publications.

Submission Preparation Checklist

As part of the submission process, authors are required to check off their submission's compliance with all of the following items, and submissions may be returned to authors that do not adhere to these guidelines.

1. The submission has not been previously published, nor is it before another journal for consideration (or an explanation has been provided in Comments to the Editor).
2. The submission file is in OpenOffice, Microsoft Word document file format.
3. The text adheres to the stylistic and bibliographic requirements outlined in the [Author Guidelines](#), which is found in About the Journal.
4. The ORCID ID of the authors or at least the first and corresponding authors have been assigned
5. One author has been designated as the corresponding author with contact details: E-mail address, Full postal address, Phone numbers
6. All necessary parts are considered, and contain: Highlights; Title page; Abstract and keywords; Running Title; Main

manuscript; Figure captions; All figures;
All tables

7. Manuscript has been 'spell-checked' and 'grammar-checked'
8. All references mentioned in the Reference list are cited in the text, and vice versa. References are in the correct format for this journal
9. Permission has been obtained for use of copyrighted material from other sources
10. A covering letter with all needed items is prepared

Copyright Notice

Upon publication, author(s) agree that the journal of *Trends in Peptide and Protein Sciences* is the copyright owner of the material published. All works published in the TPPS are open access and are available to anyone on the web site of the journal without cost. The users are free to use the work, subject to proper attribution of authorship and ownership of the rights. Authors may use their material in presentations and subsequent publications they write or edit themselves, provided that the TPPS is referenced in writing and is acknowledged as the original publication.

Creative Common Attribution Non-Commercial 4.0 International License (CC BY-NC 4.0)

This is an open access journals that articles distributed under the terms of [Creative Common Attribution Non-Commercial 4.0 International License](#) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work properly cited.

Privacy Statement

The names and email addresses entered in the journal site will be used exclusively for the stated purposes of this journal and will not be made available for any other purposes or to any other parties.

Preprint Policy

A preprint is considered as an author's version of a manuscript prior to the version accepted for publication in a journal. Authors are allowed to deposit an initial draft of their manuscript anywhere. However, authors should disclose the Digital Object Identifier (DOI) once the manuscript is submitted to the journal or at any other point during the peer review process at TPPS. If the manuscript is accepted for publication, the preprint record should be updated with the DOI and a URL link to the published version of the article on the journal website. Please note that However, deposition of a preprint shall not be viewed as prior publication.

Checking List

Ensure that the following items are prepared:

- One author has been designated as the Corresponding Author with contact details:
E-mail address
Full postal address
Phone and fax numbers
ORCID ID

Contact us:

School of Pharmacy, Shahid Beheshti University of Medical Sciences, Protein Technology Research Center (PTRC); Vali Asr Avenue, Niayesh Junction, Tehran, Iran.

Postal Code: 19968-35113

POBox: 14155-6153, IRAN

TEL : + 98 -21- 88648124, 88647823 (8 a.m. to 4 p.m. Tehran, GMT+3:30)

FAX: + 98 21 88647456

Whats App: +98 9380414297

Email: tipps@sbmu.ac.ir



[linkedin.com/in/journal-trends-in-peptide-and-protein-sciences-314817216](https://www.linkedin.com/in/journal-trends-in-peptide-and-protein-sciences-314817216)

Principal Contact

Prof. Bahram Kazemi

Editor-in-Chief

Phone: +98-21-22439956

tipps@sbmu.ac.ir

Support Contact

Maryam Tabarzad, PhD

Phone: +98-21-88648124

m_tabarzad@sbmu.ac.ir

tabarzad.m@gmail.com